Back

Efficacy and Safety of Middle Meningeal Artery Embolization for Patients with Chronic Subdural Hematoma: A Systematic Review and Meta-Analysis

Kabir, N.; Owais, B.; Trifan, G.; Testai, F. D.

2024-07-24 neurology
10.1101/2024.07.23.24310607 medRxiv
Show abstract

BackgroundChronic subdural hematoma (CSDH) is characterized by the collection of blood beneath the dura mater. Traditional treatments involve surgical drainage of the hematoma, but recurrence rates can be high. A highly vascularized neo-membrane irrigated by the middle meningeal artery (MMA) may be involved in CSDH re-accumulation. ObjectiveWe conducted a systematic review and meta-analysis of studies that compared the efficacy and safety of MMA embolization to conventional treatment alone for CSDH. Material and MethodsA systematic search of PubMed, Embase Ovid, and ClinicalTrials.gov identified observational and randomized clinical studies comparing MMA embolization to conventional treatment for chronic subdural hematoma. The efficacy outcomes were hematoma recurrence and good functional outcome (as defined by a modified Rankin Scale score (mRS) of 0-2). Safety outcomes were the rate of major complication and mortality. Heterogeneity among studies were evaluated using the I2 statistic. Analyses were conducted using Cochrane Review Manager software, with risk ratios (RR) and 95% confidence intervals (95% CI) presented for key outcomes. Absolute risk reduction (ARR, 95% CI) 1000 patients were also calculated using GRADEpro software. ResultsThe analysis included data from 13 studies (4 RCTs and 9 observational studies) with a total number of 2960 patients (35.3% in the MMA group and 64.7% in the conventional treatment group). Compared to conventional treatment, MMA embolization decreased risk of hematoma recurrence by 60% (13 studies, RR=0.40, 95% CI 0.25-0.63; I2=50%), for an absolute effect of 119 fewer events/1000 patients (95% CI 70-149), with similar risk of major complications (9 studies, RR=0.82, 95% CI=0.54-1.25) and mortality risk (13 studies, RR=0.90, 95% CI=0.54-1.51). In subgroup analyses by study type, pooled results from RCTs showed similar direction effects as those from observational studies for both efficacy and safety outcomes. ConclusionMMA embolization in CSDH management is a safe and effective approach for CSDH.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
PLOS ONE
4510 papers in training set
Top 18%
10.2%
2
Neurocritical Care
11 papers in training set
Top 0.1%
8.5%
3
Journal of the Neurological Sciences
17 papers in training set
Top 0.1%
8.5%
4
Stroke: Vascular and Interventional Neurology
13 papers in training set
Top 0.1%
6.9%
5
Frontiers in Neurology
91 papers in training set
Top 1%
4.9%
6
Medicine
30 papers in training set
Top 0.5%
3.7%
7
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.3%
3.7%
8
Journal of Stroke and Cerebrovascular Diseases
12 papers in training set
Top 0.2%
3.6%
9
BioMed Research International
25 papers in training set
Top 0.7%
3.6%
50% of probability mass above
10
BMC Neurology
12 papers in training set
Top 0.1%
3.6%
11
Scientific Reports
3102 papers in training set
Top 40%
3.3%
12
Stroke
35 papers in training set
Top 0.4%
3.1%
13
Journal of Neurology
26 papers in training set
Top 0.3%
2.8%
14
Journal of Neurotrauma
27 papers in training set
Top 0.3%
2.1%
15
Journal of Clinical Medicine
91 papers in training set
Top 3%
1.8%
16
Journal of the American Heart Association
119 papers in training set
Top 3%
1.7%
17
European Journal of Neurology
20 papers in training set
Top 0.3%
1.3%
18
Biomedicines
66 papers in training set
Top 1%
1.3%
19
F1000Research
79 papers in training set
Top 3%
1.2%
20
Annals of Oncology
13 papers in training set
Top 0.7%
1.2%
21
Cureus
67 papers in training set
Top 3%
1.2%
22
BMJ Open
554 papers in training set
Top 12%
0.8%
23
Neurology
44 papers in training set
Top 1%
0.8%
24
Annals of Translational Medicine
17 papers in training set
Top 1%
0.7%
25
Ultrasound in Medicine & Biology
10 papers in training set
Top 0.6%
0.7%
26
The Innovation
12 papers in training set
Top 1%
0.6%
27
Neuroinformatics
40 papers in training set
Top 1%
0.6%
28
Frontiers in Integrative Neuroscience
12 papers in training set
Top 0.7%
0.5%
29
Diagnostics
48 papers in training set
Top 3%
0.5%
30
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 1%
0.5%